Adecoagro SA vs Inovio Pharmaceuticals Inc — how do they compare? Adecoagro SA trades at $9.24 (market cap $1.36B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: Adecoagro SA is far larger — about 17.3× Inovio Pharmaceuticals Inc's market cap, and Adecoagro SA pays a 3.15% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AGRO | INO | |
|---|---|---|
Market Cap | $1.36B | $78.55M |
Sector | Technology | Health |
52-Week High | $15.25 | $2.87 |
52-Week Low | $7.13 | $0.66 |
Enterprise Value | $3.39B | $49.56M |
Dividend Yield | 3.15% | — |
Signals from Pluang's Aura AI — not financial advice
AGRO trades at $9.29, down 3.83% today, with a bearish technical signal and mixed earnings performance. The company reported strong adjusted EBITDA growth in Q2 2026 ($172.5M) and is expanding via acquisition of the Caarapó mill. However, recent quarters show earnings misses against expectations, with net income margin at just 0.91% for 2026. Valuation metrics appear reasonable with P/S of 0.71 and P/B of 0.77, but high P/E of 522.78 reflects profitability challenges.
The outlook remains cautious with analyst consensus leaning toward Hold (50%) amid execution risks from recent acquisitions and commodity volatility. Positive catalysts include operational efficiency gains and expansion in South American markets, but investors face headwinds from elevated leverage and macroeconomic sensitivity to oil and gas prices.
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Trailing returns across standard periods
Latest headlines on both assets
Adecoagro is a South American agricultural company. It operates a diversified business including farming crops, rice, and dairy, as well as producing sugar, ethanol, and renewable energy from its industrial facilities.
Read more on AGRO →Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →